Most Read This Week
- Outcomes of Neratinib + Fulvestrant + Trastuzumab and Biomarker Analysis in Patients With HR+/HER2−, HER2-Mutant MBC
- Outcomes of CDK4/6 Inhibitors vs Weekly Paclitaxel in the Treatment of Patients With ER+/HER2− Advanced Breast Cancer With Impending or Established Visceral Crisis
- Efficacy and Safety of CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-Line Treatments for Patients With HR+/HER2− Advanced Breast Cancer
- Utility of a Risk-Stratification Model for Predicting Overall Survival Outcomes in Young Women With Stage IV Breast Cancer
- Intermediate-Term Outcomes of Permissive Cardiotoxicity in Patients With Breast Cancer Receiving Trastuzumab
Recently Updated
- Diagnostic Value of Serum Alkaline Phosphatase and Bone-Specific Alkaline Phosphatase Levels for Metastases in Patients With Breast Cancer
- Plasma APOM Predicts Overall Survival Outcomes in Patients With Metastatic Breast Cancer
- Intermediate-Term Outcomes of Permissive Cardiotoxicity in Patients With Breast Cancer Receiving Trastuzumab
- Overall Survival With Sacituzumab Govitecan in Patients With Pretreated, Endocrine-Resistant, HR+/HER2− Metastatic Breast Cancer
- Efficacy and Safety of CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-Line Treatments for Patients With HR+/HER2− Advanced Breast Cancer